Immunomodulatory Effect of “Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Therapy” to Cure or Prevent Hospital Acquired (Nosocomial) Infections due to Clostridium difficile (C. diff), other Pathogenic Bacteria, and Autoimmune Diseases
DOI:
https://doi.org/10.37285/ijpsn.2018.11.1.1Abstract
The worldwide popularity of Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Therapy to treat or prevent the hospital acquired infections (nosocomial infections) arose a great interest in the medical community around the world (Reddy and Reddy, 2016; 2017). The following questions were raised on this subject: Does Multiple Mixed Strain Probiotics directly inhibit the pathogenic bacteria (C. diff) in the gastrointestinal tract or indirectly through modulation of the host immune system or both? To be more specific, what is the exact and/or hypothetical mechanism at molecular level behind the breakthrough discovery of Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Therapy? To answer these questions, the specific immunomodulation regulatory functions of the individual Probiotic strains (on host) have beenresearched, investigated andoutlined in this article. A detailed explanation(s) and hypotheses have been proposed outlining the possible cumulativedirect bacteriological and indirect immunomodulatory effects (at the molecular level) of the Multiple Mixed Strain Probiotics used in Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Therapy to successfully treat C. diff infection. A detailed scientific and research attempts were made to correlate the Probiotic induced immune activities in relation to the reduction of the symptoms associated with the hospital acquired Clostridium difficile infection during and after the Multiple Mixed Strain Probioitc Therapy. Results of the clinical trials, microbiological tests on feces, and the clinical blood tests significantly revealed that the reasons for the success of Dr. Reddy’s Multiple Mixed Strain Probiotic Therapy are multifold. Presumably, it is predominantly due to the immunomodulatory effect they have exerted on the host immune system along with the direct inhibition of C. diff bacteria by multiple Probiotics, due to the production of bacteriocins, lactic acid and nutritional competency.In addition, the size of the individual cells of the Probiotic strains in the Multiple Mixed Strain Probiotics and their significant effect on immunomodulation has been thoroughly discussed. Results clearly proved that if Probiotics are absent in the GI tract during C. diff infection, the chances of patient survival is zero. This is because of the excess immune stimulation and incurable damage to the epithelial cell barrier of the gastrointestinal tract caused by C. diff bacteria. The results also revealed, without any doubt, as of to-datethe latest discovery of Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Therapy is the best way to cure the deadly hospital acquired infections affecting millions of people around the world, with high degree of mortality. This has been attested by several practicng medical professionals and scientists around the world (Reddy and Reddy, 2017).
Downloads
Metrics
Keywords:
Autoimmune diseases., Immune stimulation, Immune tolerance, Probiotics, Nosocomial infections, MRSA (Methicillin Resistant Staphylococcus Aureus), C. diff (Clostridium difficile), Hospital acquired infections, Fecal Microbiota Therapy (FMT), Para Probiotics, Probiotic therapy, Hygiene hypothesis, CD8 cytotoxic cells, CD4 TH cells, Regulatory T-cells, Neurotransmitters, Gut-brain axis, Cytokines, Immunomodulins, Bacteriocins, Multiple Mixed Strain Probiotic Therapy
Downloads
Published
How to Cite
Issue
Section
References
Berer K, Mues M, Koutrolos M, Rasbi Z, Boziki M, and Johner C (2011). Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 479: 538-541.
Bienenstock J and Collins S (2010).99thDahlem Conference on Infection, Inflammation and Chronic Inflammatory Disorders: Psycho-Neuroimmunology and the Intestinal Microbiota: Clinical observations and basic mechanisms. Clin Exp Immunol 160: 85-91.
Bravo J, Forsythe P, Chew M, Escaravage E, Savignac H and Dinan T (2011). Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl AcadSci USA108: 16050-16055.
De Simone C and Bianchi-Salvadori B (1989). Modulation of immune activities in humans and animals by dietery lactic acid bacteria. In: Chandan RC, ed. Yogurt: nutritional and health properties. McLean VA: Kirby. Lithographics: 201-214.
Forsythe P, Sudo N, Dinan T, Taylor V and Bienenstock J (2009). Mood and gut feelings. Brain BehavImmun 24: 9-16.
Frank D, Zhu W, Sartor R and Li E (2011). Investigating the biological and clinical significance of human dysbioses. Trends Microbiol19: 427-434.
Hardy H, Harris J, Lyon E, Beal J and Foey AD(2013).Probiotics, prebiotics and immunomodulation of gut mucosal defenses: Homeostasis and Immunopathology. Nutrients5:1869-1912.
Hemarajata P and Versalovic J (2013). Effects of Probiotics on gut micorbiota: mechanism of intestinal modulation and neuromodulation. TherAdvGastroenterol 6(1): 39-51.
Higuchi T, Hayashi H and Abe K (1997). Exchange of glutamate and gamma-aminobutyrate in a Lactobacillus strain. J Bacteriol 179: 3362-3364.
Lee B and Bak Y (2011). Irritable bowel syndrome, gut microbiota and probiotics. J NeurogastroenterolMotil 17: 252-266.
Liana V-B, Florica P and Catalina B(2013). Probiotics and their immunodulatory potential. Current Health Sci J 39(4): 204-209.
Lin Y, Thibodeaux C, Pena J, Ferry G and Versalovic J (2008). Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. Inflamm Bowel Dis 14: 1068-1083.
Liu Y, Fatheree N, Mangalat N and Rhoads J (2010). Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation. Am J PhysiolGastrointest Liver Physiol 299: G1087-G1096.
Livingston M, Loach D, Wilson M, Tannock G and Baird M (2009). Gut commensal Lactobacillus reuteri 100–23 stimulates an immunoregulatory response. Immunol Cell Biol 88: 99-102.
Okada H, Kuhn C, Feillet H and Bach J(2010). The hygiene hypothesis for autoimmune and allergic diseases: an update. Clinexpimmunol 160:1-9.
Ott SJ, Waetzig GH and Rehman A (2017). Efficacy of sterile fecal transfer for treating patients with Clostridium difficile infection. Gastroenterol152: 799-811.
Rautava S, Arvilommi H and Isolaur E (2006). Specific Probiotics in enhancing maturation of IgA responses in formula-fed infants. Pediatr Res 60: 221-224.
Reddy MS, Washam CJ, Reinbold GW and Vedamuthu ER (1973). Immunogenic properties of slime from Propionibacterium. J Milk Food Technol 36: 200-201.
Reddy MS and Reddy DRK (2016).Dr. M.S. Reddy’s Multiple Mixed StrainProbiotic Therapy. J Pharmaceutics and Nanotechnol 4(3): 15-28.
Reddy MS and Reddy DRK (2017). An insight into the 2016 Best Medical awardwinning Breakthrough Microbial and Nano Technology based discovery of Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Therapy, to successfully treat theNosocomial infections. Nano Technol and Nano Sci J 1(1): 2-5.
Reddy MS (2017). An approach to osteopenia and osteoporosis. AAPI Journal (fall issue) 8: 26-27.
Reddy MS and Reddy DRK (2015). Therapeutic Probiotics for cancer reduction. AAPI Journal 6: 36-39.
Reddy MS, Reddy DRK and PradadNav(2000). Herbal and pharmaceutical drugs enhanced with Probiotics. US patent 6080401: 1-48.
Reddy MS and Reddy DRK (2009). Probiotic therapy. AAPI Journal 3: 28-29.
Reddy MS and Reddy DRK (2011). Antiaging: a review and experimental clinical study of bioavailable calcium, probiotics, and their effect on reversing osteopenia, osteoporosis, and other common health conditions. Int J Pharma Sci Nanotech 4: 1436-1444.
Reddy MS and Reddy DRK (2016). Development of Multiple Mixed Strain Probiotics for “Probiotic therapy” under clinical conditions, to prevent or cure the deadly hospital acquired infections dutie to Clostridium difficile (C. diff) and Methicillin Resistant Staphylococcus Aureus (MRSA). Int J Pharma Sci Nanotech 9: 3256-3281.
Reddy MS and Reddy DRK (2016). Isolation and determination of the major principle of causative agent behind the 2016 published breakthrough discovery of Dr. M.S. Reddy’s “Multiple Mixed Strain Probiotic Therapy” in successfully treating the lethal hospital acquired infections due to Clostridium difficile (C. diff) and Methicillin Resistant Staphylococcus Aureus (MRSA). Int J Pharma Sci Nanotech 6: 3556-3566.
Reddy MS (2017). Chronic stress-an etiological agent for the genesis of multitude of diseases, and the effect of meditation on modulating the stress. Open Acc J Toxicol 1(5): 555-571.
Rodriguez AC, Cara DC, Fretez SH, Cunha FQ, Vieira EG, Nicoli JR and Vieira LQ (2000). Saccharomyces boulardii stimulates SIgA production and the phagocytic system of gnotobiotic mice. J ApplMicrobiol 89: 404-414.
Saavedra JM and Bauman NA (1994). Feeding of Bifdobacteriumbifidum and Streptococcus thermophillus to infants in hospital for prevention of diarrhea and shedding of rotavirus. Lancet 344: 1046-1049.
Schultz M and Linde HJ (2003). Immunomodulatory consequences of oral administration of Lactobacillus rhamnosus strain GG in healthy volunteers. J. Dairy Res 70: 165-173.
Schiffrin EJ and Link-AmsterH (1995). Immunomodulation of human blood cells following the ingestion of lactic acid bacteria. J Dairy Sci 78: 491-497.
Schultz M and Linde H (2003). Immunomodulatory consequences of oral administration of Lactobacillus rhamnosus strain GG in healthy volunteers. J Dairy Res 70: 165-173.
Sharma A, Lelic D, Brock C, Paine P and Aziz Q (2009). New technologies to investigate the brain–gut axis. World J Gastroenterol 15: 182-191.
Smith MA, Simon R, Strickler HD, McQullan G, GloecklerRies LA and Linet MS (1998). Evidence that childhood acute Lymphoblastic leukemia is associated with an infectious agent linked to hygiene conditions. Cancer Causes and Control 9(3): 285-298.
Solis-Pereyra B and Lemonnier D (1993). Induction of human cytokines by bacteria used in dairy foods. Nutr Res 13: 1127-1140.
Thomas C, Hong T, Van Pijkeren J, Hemarajata P, Trinh D and Hu W (2012). Histamine derived from probiotic Lactobacillus reuteri suppresses TNF via modulation of Pka and Erk signaling. PLoSONE 7: e31951
Valeur N, Engel P, Carbajal N, Connolly E and Ladefoged K (2004). Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. Appl Environ Microbiol 70: 1176-1181.
